CYTOCARB
CARBOPLATIN · by A. J. MIRZA
Composition
Inj 10 mg/50 mg/150 mg/200 mg/450 mg: Per vial: Carboplatin 10 mg/50 mg/150 mg/200 mg/ 450 mg.
Indications & Dosage
Treatment of advanced ovarian cancer and lung cancer (particularly the small cell type), head and neck cancers, bladder carcinoma, testicular carcinoma and when cisplatin cannot be administered: BY IV INF: Adult: Monotherapy: 360 mg/m2 IV on day 1, then every 4 weeks. Combination Therapy: 300 mg/m2IV on day 1, then every 4 weeks x 6 cycles. The dose of carboplatin is determined according to renal function rather than body surface area, dose adjustment based on platelet & neutrophil count (consult product literature).
Administration
Administer as IV push or bolus over 15 min up to a continuous intravenous infusion over 24 hour, reconstitute powder to yield a final concentration of 10 mg/ml. May also be administered intraperitoneally. When administered as swquential infusions, tisane derivatives (docetaxel, paclitacel) should be administered before platinum derivatives to limit myelosuppression and to enhance efficacy. Do not use needles or IV administration sets containing aluminium parts that may come in contact with carboplation (aluminium can react causing precipitate formation and losss of potency)
Compatibility
Stable in D51/2 NS, D5NS, D5W, NS.
Stability
Store at 25C (77F). Protect from light. Use carboplation solutions within 8 hours of reconstitution or preparation when stored at room temperature (25C; 77F), excursions permitted from 15C -30C (59F-86F ). When stored in the original multi dose vial, the commercially available solution is stable for up to 14 days at room temperature even with multiple needle entries.
Contraindications
Severe allergy to platinum components or mannitol.
Precautions
Peripheral blood conunts, renal and neurological function to be monitored closely.
Pregnancy
Positive evidence of risk: Avoid
Lactation
Contraindicated. Discontinue breast-feeding.
Side Effects
Alopecia, bone-marrow suppression, extravasation, hyperuricaemia, myelosuppression, nausea, nephrotoxicity, neurotoxicity, oral mucositis, ototoxicity, thromboembolism, tumourlysis syndrome, vomiting